1. Signaling Pathways
  2. Protein Tyrosine Kinase/RTK
  3. Bcr-Abl
  4. Abl Isoform



Abl Related Products (13):

Cat. No. Product Name Effect Purity
  • HY-13520
    Inhibitor 99.66%
    Nocodazole (Oncodazole) is a rapidly-reversible inhibitor of microtubule.
  • HY-50514
    Inhibitor 99.70%
    AT9283 is a multi-targeted kinase inhibitor with potent activity against Aurora A/B, JAK2/3, Abl (T315I) and Flt3 (IC50s ranging from 1 to 30 nM).
  • HY-10339
    Inhibitor 99.85%
    KW-2449 is a multi-targeted kinase inhibitor of FLT3, ABL, ABLT315I and Aurora kinase with IC50s of 6.6, 14, 4 and 48 nM, respectively.
  • HY-112089
    Inhibitor 99.95%
    LXH254 is a potent, selective, orally active, type II BRAF and CRAF inhibitor, with IC50 values of 0.072 and 0.21 nM against CRAF and BRAF, respectively.
  • HY-13905
    Flumatinib mesylate
    Inhibitor 99.87%
    Flumatinib (HHGV678) mesylate is an orally active and selective inhibitor of Bcr-Abl.
  • HY-10363
    AP 24149
    AP 24149 is a potent Src-Abl dual inhibitor with IC50 values of 9.1, 3.6 nM for Src and Abl, respectively.
  • HY-122113
    PD173952 is a tyrosine kinases inhibitor with IC50s of 0.3, 1.7 and 6.6 nM against Lyn, Abl and Csk, respectively.
  • HY-108766
    Ponatinib hydrochloride
    Inhibitor 99.26%
    Ponatinib (AP24534) hydrochloride is a hydrochloride of ponatinib.
  • HY-119370
    CHMFL-ABL-121 is a highly potent type II ABL kinase inhibitor with IC50s of 2 nM and 0.2 nM against purified inactive ABL wt and T315I kinase protein, respectively.
  • HY-14979A
    ML786 dihydrochloride
    ML786 dihydrochloride is a potent and orally bioavailable Raf inhibitor, with IC50s of 2.1, 4.2, and 2.5 nM for V600EΔB-Raf, wt B-Raf, and C-Raf, respectively.
  • HY-101268
    CHMFL-ABL-053 (Compound 18a) is a potent, selective, and orally available BCR-ABL, SRC and p38 kinase inhibitor with IC50 values of 70, 90 and 62 nM against ABL1, SRC and p38, respectively.
  • HY-146697
    IHMT-TRK-284 (Compound 34) is a potent, orally active type II TRK kinase inhibitor with IC50 values of 10.5, 0.7, and 2.6 nM to TRKA, B, and C respectively.
  • HY-111874
    SNIPER(ABL)-039, conjugating Dasatinib (ABL inhibitor) to LCL161 derivative (IAP ligand) with a linker, induces the reduction of BCR-ABL protein with a DC50 of 10 nM.